IBN Coverage: Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform
LOS ANGELES, CA - May 20, 2025 ( NEWMEDIAWIRE ) - Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans - a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as transformative, helping him confront trauma and save his marriage. Now in Congress, he's pushing for science-based, medically supervised access to Schedule I drugs like ibogaine, psilocybin, and MDMA. Joined by fellow veterans in office, including Rep. Dan Crenshaw (R-Texas) and Rep. Jack Bergman (R-Mich.), Luttrell is helping lead legislative efforts to fund clinical trials through the VA and Pentagon, despite resistance from some conservatives and recent regulatory setbacks like the FDA's rejection of an MDMA therapy from Lykos Therapeutics.
Amid this shift, NRx Pharmaceuticals (NASDAQ: NRXP) and its subsidiary HOPE Therapeutics are emerging as leaders in veteran-focused psychedelic innovation. HOPE is developing ketamine-based treatments for acute suicidality and major depression and is building a nationwide network of…
Read More
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to NRXP are available in the company's newsroom at https://ibn.fm/NRXP
Forward Looking Statements
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
About IBN
IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients.
IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions.
For more information, please visit www.IBN.fm
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
Media Contact
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Immunis Named Among Top 25 Biotech & Life Sciences Companies for 2025 by The Healthcare Technology Report
IRVINE, Calif.--(BUSINESS WIRE)-- Immunis, Inc., a clinical-stage biotech pioneering multi-active stem cell-derived biologics for age and disease-related immune dysregulation, was honored as one of the 'Top 25 Biotech & Life Sciences Companies for 2025' by The Healthcare Technology Report. This award is highly regarded by corporate executives, institutional investors, and industry leaders, cementing Immunis' reputation as a groundbreaking force in biomedical innovation. Immunis received the accolade based on the ingenuity of its investigational stem cell-derived secretome therapy, IMM01-STEM, which aims to address age–related muscle atrophy, a disease that will affect 100% of humans. Share The Healthcare Technology Report (HTR) is a respected market research firm that reports on the developments, corporate actions, investment activity, and executive insights related to the healthcare industry. Awardees are chosen following an intensive evaluation of product innovation, leadership, strategic impact, and contributions to the global advancement of patient healthcare. Immunis received the accolade based on the ingenuity of its investigational stem cell-derived secretome therapy, IMM01-STEM, which aims to address age–related muscle atrophy, a disease that will affect 100% of humans. Not only does Immunis have the most clinically advanced secretome therapy in the world, but it is also tackling one of the most challenging health issues for which there is no pharmaceutical cure. Impressively, Immunis is recognized alongside some of the industry's most influential biotech companies that are invoking actionable change in human healthcare. The coveted distinction inspires Immunis to continue revolutionizing patient-centered biotechnology and dismantling barriers towards its progress. About Immunis Inc. Immunis is a clinical-stage biotechnology company developing multi-active stem cell-derived biologics for the various manifestations of age-related diseases and immune dysregulation. The investigational product line leverages Immunis' leading-edge capabilities in stem cell secretome technology to deliver a product of all natural, all human immune modulators in their natural physiological concentrations. For additional information about Immunis' programs, please visit our Pipeline. Cautionary Note Regarding Forward-Looking Statements This communication contains statements that constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
Politico
an hour ago
- Politico
The MAHA wave
Driving the Day IN THE STATES — Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again campaign to combat chronic disease is reshaping state legislatures, with hundreds of bills introduced this year echoing his agenda in both red and blue states, POLITICO's Amanda Chu reports. A POLITICO analysis of state legislatures found more than 130 pieces of legislation aimed at limiting access to ultraprocessed foods and improving nutrition, over 60 measures restricting the use of pesticides and other chemicals and more than 130 measures expanding vaccine exemptions or prohibiting mandates were introduced this year. Lawmakers also introduced dozens of bills to promote the use of psychedelics, authorize sales of raw milk and the antiparasitic drug ivermectin and ban the fluoridation of drinking water. The advances seen in state capitols, often considered laboratories for federal rulemaking, offer a glimpse into how a Kennedy-run Department of Health and Human Services might turn MAHA priorities into regulation. The White House is set to release a final MAHA report, which will include recommendations to fight chronic disease. Details: POLITICO tracked nearly 900 measures on MAHA-aligned subjects that were introduced in 50 states this year — a 45 percent increase from the previous year and measures introduced in 2023 among the four states that meet every two years. Measures ranged from banning the use of food dyes to limiting children's access to social media over mental health concerns to restricting the use of mRNA, the technology behind the Pfizer and Moderna Covid-19 vaccines. The surge in state activity underscores the growing political clout of the MAHA base, which cuts across party lines, and offers MAHA supporters a chance to secure policy wins outside a White House navigating competing interests. Following intense pressure from agricultural lobbyists, the Trump administration assured farm groups earlier this summer that the final MAHA report would include no new policy around pesticide use despite linking the chemical to cancer in a May draft report. Bipartisan appeal? Blue states New York and New Jersey led the country in the number of MAHA-aligned measures introduced this year, followed by Republican-led Texas. While some topics, like ending vaccine mandates, were predominantly backed by one party, a few themes had bipartisan traction: Roughly a third of measures to improve nutrition and restrict food additives were sponsored by at least one member of each party this year. 'We see so much state activity. … It's bipartisan. They're tapping into something that most Americans know intuitively. MAHA will persist when Kennedy is gone in the future,' said Joel White, a Republican health care strategist and founder of Horizon Government Affairs, a Washington lobbying firm. WELCOME TO THURSDAY PULSE. Adults in the U.S. are drinking less and worrying more about alcohol's health effects, according to new numbers from Gallup. Send your tips, scoops and feedback to khooper@ and sgardner@ and follow along @kelhoops and @sophie_gardnerj. At the White House PRASAD BACKSTORY — White House chief of staff Susie Wiles advocated to bring back the FDA's top vaccine regulator, Dr. Vinay Prasad, after he was pushed out following social media attacks from MAGA influencer Laura Loomer, POLITICO's David Lim, Dasha Burns and Tim Röhn report. Wiles' decision to advocate on Prasad's behalf, as described to POLITICO by two senior administration officials granted anonymity to discuss sensitive details, came after pleas from both Prasad's boss, FDA Commissioner Marty Makary, and Health Secretary Robert F. Kennedy Jr. They insisted that Prasad is part of Kennedy's broader Make America Healthy Again movement to combat chronic diseases and integral to the Trump coalition. Loomer did not respond immediately to a request for comment. The FDA referred questions to the White House. 'Secretary Kennedy and the entire HHS team are doing a terrific job as they deliver on President Trump's mandate to Make America Healthy Again,' White House spokesperson Kush Desai said. 'Scores of prominent restaurant chains and food brands dropping artificial ingredients from our food supply and historic reforms at the FDA to fast-track lifesaving drugs and treatments prove that the entire HHS team is delivering for the American people.' Background: President Donald Trump forced Prasad out of his FDA job less than two weeks earlier after the Cambridge, Massachusetts, pharmaceutical manufacturer Sarepta Therapeutics, joined by GOP allies and Loomer, sought his ouster. He abruptly returned last week. Read the full story here. DRUG STOCKPILE EO — President Donald Trump issued an executive order Wednesday aimed at bolstering the domestic supply of drugs by ordering his health department to fill a drug-ingredient stockpile he established during his first term, POLITICO's Lauren Gardner reports. The directive builds on the Strategic Active Pharmaceutical Ingredients Reserve that Trump established in 2020 during the Covid-19 pandemic when shortages of medical supplies and devices hampered the pandemic response. The U.S. relies largely on China, India and the European Union for APIs, particularly those that go into commonly used generic medicines like antibiotics and chemotherapies that are manufactured on low margins. Details: The order directs the Office of the Assistant Secretary for Preparedness and Response — the HHS agency that focuses on emergency readiness — to develop a list of 'approximately' 26 drugs considered critical to domestic health and security interests. It calls for an accounting of available funding that can be used to open the stockpile and to secure and maintain a six-month supply of active pharmaceutical ingredients needed to make the critical drugs. In Congress PRO MEDICAID CUTS — An influential group of Republicans has invited a key proponent of slashing Medicaid to brief congressional aides as the GOP mulls a potential second reconciliation bill, POLITICO's Benjamin Guggenheim and Meredith Lee Hill report. Brian Blase, president of the conservative think tank Paragon Health Institute, is set to address staff Thursday at a briefing on health care reform hosted by the Republican Study Committee, according to an invitation obtained by POLITICO. Blase was allied with conservative hard-liners earlier this year in pushing for significant cuts to Medicaid in the first GOP package. He was the initial author of a letter arguing for 'structural' changes to the program that Rep. Chip Roy (R-Texas) and 19 other hard-right members later sent to their House Republican colleagues. Details: An RSC spokesperson declined to comment on Thursday's briefing. But a person granted anonymity to discuss plans in advance said the meeting is set to cover enhanced tax credits for Affordable Care Act health insurance premiums, which are due to expire at the end of the year, as well as rules governing the percentage of Medicaid expenditures covered by the federal government and reimbursed to states. Not unprecedented: The RSC, composed of 189 House conservatives, has been a key force pushing for a follow-on to President Donald Trump's 'big, beautiful bill' that was signed into law last month. The group has invited several conservative experts to address staffers in recent weeks, though it has yet to endorse any specific health care policies for any forthcoming package. Those staff-level meetings continue as House GOP leaders try to plot a way forward amid skepticism over whether another sprawling domestic policy bill is even possible, given the difficulties Republicans had coming to an agreement on the first bill. Looking forward: It's still unclear what health topics a possible second package would address. Some House GOP factions are discussing further slashing Medicaid as well as possibly targeting Medicare funding. AROUND THE AGENCIES MAHA REPORT TIMELINE — The White House told several agricultural industry representatives to expect the latest Make America Healthy Again report to be publicly released in September, according to two people familiar with the conversation, POLITICO's Grace Yarrow reports. Some farm groups were recently invited to the White House and given 20 to 30 minutes to view a hard copy of a draft strategy report, said the two people, who were granted anonymity to share private details. The draft report that groups have seen is roughly 15 pages and has only 'light' mentions of pesticides, one of the two people said. But given that officials plan to wait for weeks before publishing the report, anything could change. Farm groups are crossing their fingers that the MAHA Commission won't scale up plans last minute to crack down on pesticides. 'If the ag community felt like they'd had some success in mitigating some of the worst language, or even taking some of that stuff out, an extra month may not feel like an opportunity,' said one of the people. 'It actually might feel like a bigger risk, because if they're already comfortable with where it sits now, what does an extra month mean?' 'On the other side, the MAHA folks are going to be pushing for more aggressive policy solutions across the board,' the person added. 'Maybe it would have been better for it to just pop out as it is.' Buckle up: Behind the scenes, the White House is taking extra time to review the policy recommendations to 'make sure it's not fucked up like last time,' as one person familiar with the process told our Dasha Burns, referencing the first error-riddled report from the MAHA Commission earlier this year. An HHS official told our Playbook colleagues that 'the team at the White House and HHS is ensuring that whatever is in the report is the best possible product for the American people. If they need more time, they need more time.' WHAT WE'RE READING The New York Times' Roni Caryn Rabin and Irena Hwang report on the Trump administration halting research related to racial and socio-economic disparities.
Business Wire
2 hours ago
- Business Wire
Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) ('Alpha Cognition' or the 'Company') today announced its financial results for the second quarter ended June 30, 2025. 'The initial ZUNVEYL launch has been met with strong interest from both healthcare providers and patients. Early adoption in nursing homes and by geriatric specialists has created a solid foundation for future growth,' said Michael McFadden, Chief Executive Officer of Alpha Cognition. 'Clinician feedback continues to validate our belief that ZUNVEYL will become an important therapy in the long-term care segment.' Recent Business and Operational Highlights Completed the first quarter of ZUNVEYL commercialization, achieving approximately $2 million in net product revenues year-to-date. Received positive clinician feedback highlighting ZUNVEYL's impact on cognitive function, behavioral symptoms, and its safety profile. Secured the Company's first national Medicare Part D contract with no prior authorization required, ahead of schedule. Sales team engaged with more than 3,700 healthcare professionals and generated prescriptions in over 300 nursing homes. Concluded the Bomb Blast Study, demonstrating that ALPHA-1062 reduced neuroinflammation and neuropathology associated with blast trauma. Second Quarter 2025 Financial Results: ZUNVEYL net product revenues of $1.6 million for the quarter ended June 30, 2025. Research and development expenses for the three months ended June 30, 2025 were $317 thousand compared to $967 thousand for the same period in 2024. Selling, general and administrative expenses for the three months ended June 30, 2025 were $6.5 million compared to $1.4 million for the same period in 2024, driven primarily by commercial-readiness activities. Net operating loss for the three months ended June 30, 2025 were $5.7 million compared to $2.4 million for the same period in 2024. Net loss for the for the three months ended June 30, 2025 were $10.5 million compared to $2.1 million for the same period in 2024, primarily due to a $5.2 million non-cash change in the value of warrant liabilities. Cash and cash equivalents of $39.4 million as of March 31, 2025 compared to $48.6 million as of December 31, 2024. At current utilization rate, the Company expects a cash runway of approximately two years. Following the release, management will host a conference call to review financial and operating results. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury ('mTBI'), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ZUNVEYL's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. INDICATION AND USAGE ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred. WARNINGS AND PRECAUTIONS Serious Skin Reactions: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered. Anesthesia: See Drug Interactions Section Cardiovascular Conditions: Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction. Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope. Gastrointestinal Conditions: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding. Galantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. Monitor the patient's weight during therapy with ZUNVEYL. Genitourinary Conditions: Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction. Neurological Conditions: Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer's disease. Patients with Alzheimer's disease should be monitored closely for seizures while taking ZUNVEYL. Pulmonary Conditions: Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions. ADVERSE REACTIONS The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. DRUG INTERACTIONS Use with Anticholinergics: Galantamine has the potential to interfere with the activity of anticholinergic medications. Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol. USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data may cause fetal harm. Hepatic Impairment: In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended. Renal Impairment: In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended. These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'target,' 'seek,' 'contemplate,' 'continue' and 'ongoing,' or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company's intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company's filings with Canadian securities regulatory authorities and available at and the Company's filings with the United States Securities and Exchange Commission (the 'SEC'), including those risk factors under the heading 'Risk Factors' in the Company's most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025 and the Company's other filings with the SEC available at These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.
